Annonce • Jul 13
PharmaSGP Holding SE Adjusts Earnings Guidance for the Full Year 2025 PharmaSGP Holding SE adjusted earnings guidance for the full year 2025. For the year, the company decided, based on an evaluation of current data on business development completed, to adjust the forecast for consolidated revenues of the PharmaSGP Group for the full year 2025. In view of the business development to date, the Management Board now expects consolidated revenues for the 2025 fiscal year to be in the range of €132.0 million to €138.0 million. The company had previously forecasted consolidated revenues for the 2025 fiscal year in the range of €122.0 million to €128.0 million. The adjusted forecast for fiscal year 2025 continues to take into account, among other things, the ongoing high level of uncertainty in the geopolitical and global economic situation. Further developments over the course of the year and potential consequences for Germany and Europe cannot be conclusively assessed at this time. Annonce • Jun 28
PharmaSGP Holding SE Confirms Earnings Guidance for the Financial Year 2025 PharmaSGP Holding SE confirmed earnings guidance for the financial year 2025. For the year, the company expects revenues in a range between €122.0 million and €128.0 million. This represents average growth of around 5% compared with the previous year. Upcoming Dividend • Jun 19
Upcoming dividend of €0.51 per share Eligible shareholders must have bought the stock before 26 June 2025. Payment date: 01 July 2025. Payout ratio is a comfortable 30% and this is well supported by cash flows. Trailing yield: 1.8%. Lower than top quartile of German dividend payers (4.4%). Higher than average of industry peers (1.5%). Annonce • Jun 10
Futrue GmbH proposed to acquire remaining 17.91% stake in PharmaSGP Holding SE (XTRA:PSG) for €57 million Futrue GmbH proposed to acquire remaining 17.91% stake in PharmaSGP Holding SE (XTRA:PSG) from Mvh Beteiligungs- Und Beratungs-GmbH and others for €57.7 million on June 10, 2025. A cash consideration valued at €28 per share will be paid by Futrue GmbH. Upon completion, Futrue GmbH will own 100% stake in PharmaSGP Holding SE. Declared Dividend • May 16
Dividend reduced to €0.51 Dividend of €0.51 is 63% lower than last year. Ex-date: 26th June 2025 Payment date: 1st July 2025 Dividend yield will be 1.9%, which is lower than the industry average of 2.4%. Sustainability & Growth Dividend is well covered by both earnings (31% earnings payout ratio) and cash flows (25% cash payout ratio). The dividend has increased by an average of 4.3% per year over the past 3 years. However, payments have been volatile during that time. EPS is expected to grow by 44% over the next 3 years, which should provide support to the dividend and adequate earnings cover. New Risk • May 07
New minor risk - Dividend sustainability The company has an unstable dividend paying track record. The dividend has had an annual drop of over 20% in the past. Dividend yield: 2.1% This is considered a minor risk. If the company has cut or reduced its dividend in the past, it may be a sign that the underlying business is too cyclical to consistently maintain or grow the dividend over the long-term. It may also indicate the company prioritizes other outcomes instead of maintaining the dividend. For dividend paying companies, any reduction in the dividend can significantly impact the share price. Currently, the following risks have been identified for the company: Minor Risks High level of debt (122% net debt to equity). Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Reported Earnings • May 05
Full year 2024 earnings: EPS in line with analyst expectations despite revenue beat Full year 2024 results: EPS: €1.65 (up from €1.37 in FY 2023). Revenue: €119.2m (up 18% from FY 2023). Net income: €19.5m (up 19% from FY 2023). Profit margin: 16% (in line with FY 2023). Revenue exceeded analyst estimates by 4.2%. Earnings per share (EPS) were mostly in line with analyst estimates. Revenue is forecast to grow 6.2% p.a. on average during the next 3 years, compared to a 2.9% growth forecast for the Pharmaceuticals industry in Germany. Over the last 3 years on average, earnings per share has increased by 23% per year but the company’s share price has remained flat, which means it is significantly lagging earnings. Annonce • Apr 16
PharmaSGP Holding SE Provides Earnings Guidance for the Full Year 2025 PharmaSGP Holding SE provided earnings guidance for the full year 2025. For the year, the company expects a further increase in revenues in a range between €122.0 million and €128.0 million. Annonce • Apr 15
PharmaSGP Holding SE to Report Fiscal Year 2024 Final Results on Apr 30, 2025 PharmaSGP Holding SE announced that they will report fiscal year 2024 final results at 9:00 AM, Central European Standard Time on Apr 30, 2025 Reported Earnings • Nov 29
Third quarter 2024 earnings: Revenues and EPS in line with analyst expectations Third quarter 2024 results: EPS: €0.45 (up from €0.40 in 3Q 2023). Revenue: €30.3m (up 17% from 3Q 2023). Net income: €5.37m (up 12% from 3Q 2023). Profit margin: 18% (in line with 3Q 2023). Revenue is forecast to grow 7.3% p.a. on average during the next 3 years, compared to a 3.4% growth forecast for the Pharmaceuticals industry in Germany. Over the last 3 years on average, earnings per share has increased by 25% per year but the company’s share price has only increased by 2% per year, which means it is significantly lagging earnings growth. Annonce • Nov 14
PharmaSGP Holding SE to Report Nine Months, 2024 Results on Nov 28, 2024 PharmaSGP Holding SE announced that they will report nine months, 2024 results on Nov 28, 2024 Valuation Update With 7 Day Price Move • Oct 07
Investor sentiment improves as stock rises 16% After last week's 16% share price gain to €23.80, the stock trades at a forward P/E ratio of 13x. Average forward P/E is 14x in the Pharmaceuticals industry in Germany. Total returns to shareholders of 10% over the past three years. Reported Earnings • Sep 26
Second quarter 2024 earnings: EPS misses analyst expectations Second quarter 2024 results: EPS: €0.34 (up from €0.33 in 2Q 2023). Revenue: €28.2m (up 9.8% from 2Q 2023). Net income: €4.12m (up 2.5% from 2Q 2023). Profit margin: 15% (down from 16% in 2Q 2023). The decrease in margin was driven by higher expenses. Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 8.9%. Revenue is forecast to grow 6.8% p.a. on average during the next 3 years, compared to a 3.7% growth forecast for the Pharmaceuticals industry in Germany. Over the last 3 years on average, earnings per share has increased by 26% per year but the company’s share price has fallen by 1% per year, which means it is significantly lagging earnings. Annonce • Sep 12
PharmaSGP Holding SE to Report First Half, 2024 Results on Sep 26, 2024 PharmaSGP Holding SE announced that they will report first half, 2024 results on Sep 26, 2024 Price Target Changed • Jun 15
Price target increased by 9.2% to €38.75 Up from €35.50, the current price target is an average from 2 analysts. New target price is 71% above last closing price of €22.60. Stock is down 20% over the past year. The company is forecast to post earnings per share of €1.57 for next year compared to €1.37 last year. Annonce • May 18
PharmaSGP Holding SE, Annual General Meeting, Jun 26, 2024 PharmaSGP Holding SE, Annual General Meeting, Jun 26, 2024, at 10:00 W. Europe Standard Time. Reported Earnings • Apr 30
Full year 2023 earnings: EPS and revenues exceed analyst expectations Full year 2023 results: EPS: €1.37 (up from €1.00 in FY 2022). Revenue: €101.3m (up 18% from FY 2022). Net income: €16.4m (up 37% from FY 2022). Profit margin: 16% (up from 14% in FY 2022). The increase in margin was driven by higher revenue. Revenue exceeded analyst estimates by 2.4%. Earnings per share (EPS) also surpassed analyst estimates by 11%. Revenue is forecast to grow 6.7% p.a. on average during the next 3 years, compared to a 3.4% growth forecast for the Pharmaceuticals industry in Germany. Over the last 3 years on average, earnings per share has increased by 21% per year but the company’s share price has only increased by 14% per year, which means it is significantly lagging earnings growth. Declared Dividend • Apr 23
Dividend of €1.36 announced Shareholders will receive a dividend of €1.36. Ex-date: 27th June 2024 Payment date: 1st July 2024 Dividend yield will be 6.3%, which is higher than the industry average of 2.4%. Sustainability & Growth Dividend is well covered by both earnings (39% earnings payout ratio) and cash flows (23% cash payout ratio). The dividend has increased by an average of 4.3% per year over the past 2 years and payments have been stable during that time. EPS is expected to grow by 37% over the next 3 years, which should provide support to the dividend and adequate earnings cover. Annonce • Apr 21
PharmaSGP Holding SE Proposes Dividend for the Financial Year 2023 The Management Board and Supervisory Board of PharmaSGP Holding SE will propose to this year’s Annual General Meeting of the company a one-time increased dividend of EUR 1.36 per dividend-bearing share for the past financial year 2023 (previous year: EUR 0.49). Excluding treasury shares, this corresponds to a total distribution of EUR 16,320,000.00 or around 99.5% of the consolidated net income for 2023 (previous year: EUR 5,875,241.12 or 49.2% of the consolidated net income for 2022). This was decided by the Management Board and Supervisory Board. Annonce • Apr 20
PharmaSGP Holding SE Announces Changes to Dividend Policy PharmaSGP Holding SE intended to return to its previous dividend policy, according to which the distribution is generally between 30% and 50% of the consolidated net income. Annonce • Apr 16
PharmaSGP Holding SE to Report Fiscal Year 2023 Results on Apr 29, 2024 PharmaSGP Holding SE announced that they will report fiscal year 2023 results on Apr 29, 2024 Valuation Update With 7 Day Price Move • Dec 20
Investor sentiment improves as stock rises 15% After last week's 15% share price gain to €22.00, the stock trades at a forward P/E ratio of 16x. Average forward P/E is 17x in the Pharmaceuticals industry in Europe. Total loss to shareholders of 5.9% over the past three years. Reported Earnings • Nov 30
Third quarter 2023 earnings: EPS and revenues exceed analyst expectations Third quarter 2023 results: EPS: €0.40 (up from €0.33 in 3Q 2022). Revenue: €26.1m (up 19% from 3Q 2022). Net income: €4.79m (up 21% from 3Q 2022). Profit margin: 18% (in line with 3Q 2022). Revenue exceeded analyst estimates by 6.0%. Earnings per share (EPS) also surpassed analyst estimates by 21%. Revenue is forecast to grow 7.2% p.a. on average during the next 3 years, compared to a 3.7% growth forecast for the Pharmaceuticals industry in Germany. Over the last 3 years on average, earnings per share has increased by 9% per year but the company’s share price has fallen by 6% per year, which means it is significantly lagging earnings. Reported Earnings • Oct 02
Second quarter 2023 earnings released: EPS: €0.33 (vs €0.25 in 2Q 2022) Second quarter 2023 results: EPS: €0.33 (up from €0.25 in 2Q 2022). Revenue: €25.8m (up 20% from 2Q 2022). Net income: €4.02m (up 35% from 2Q 2022). Profit margin: 16% (up from 14% in 2Q 2022). The increase in margin was driven by higher revenue. Revenue is forecast to grow 7.1% p.a. on average during the next 3 years, compared to a 3.5% growth forecast for the Pharmaceuticals industry in Germany. Over the last 3 years on average, earnings per share has fallen by 2% per year but the company’s share price has fallen by 8% per year, which means it is performing significantly worse than earnings. Upcoming Dividend • Jun 22
Upcoming dividend of €0.49 per share at 1.7% yield Eligible shareholders must have bought the stock before 29 June 2023. Payment date: 03 July 2023. Payout ratio is a comfortable 45% and this is well supported by cash flows. Trailing yield: 1.7%. Lower than top quartile of German dividend payers (4.7%). Lower than average of industry peers (2.6%). New Risk • Jun 15
New minor risk - Financial position The company has a high level of debt. Net debt to equity ratio: 130% This is considered a minor risk. Having a high level of debt increases the company's balance sheet risk. The company has a higher interest repayment burden, leading to the need to allocate a greater amount of its earnings towards servicing the debt, potentially limiting growth options or shareholder distributions. It can also increase the risk of bankruptcy if business conditions deteriorate enough that the company can no longer meet its debt obligations. Currently, the following risks have been identified for the company: Minor Risks High level of debt (130% net debt to equity). Short dividend paying track record (1 year of continuous dividend payments). Major Estimate Revision • May 17
Consensus EPS estimates increase by 10% The consensus outlook for earnings per share (EPS) in fiscal year 2023 has improved. 2023 revenue forecast increased from €91.7m to €93.5m. EPS estimate increased from €1.06 to €1.17 per share. Net income forecast to grow 17% next year vs 7.5% growth forecast for Pharmaceuticals industry in Germany. Consensus price target up from €35.50 to €37.00. Share price fell 3.1% to €28.10 over the past week. Price Target Changed • May 16
Price target increased by 7.2% to €37.00 Up from €34.50, the current price target is an average from 2 analysts. New target price is 31% above last closing price of €28.20. Stock is up 16% over the past year. The company is forecast to post earnings per share of €1.17 for next year compared to €1.00 last year. Price Target Changed • Mar 31
Price target increased by 9.2% to €35.50 Up from €32.50, the current price target is an average from 2 analysts. New target price is 23% above last closing price of €28.90. Stock is up 33% over the past year. The company is forecast to post earnings per share of €0.93 for next year compared to €0.89 last year. Annonce • Jan 10
PharmaSGP Holding SE (XTRA:PSG) commences an Equity Buyback Plan, under the authorization approved on May 28, 2020. PharmaSGP Holding SE (XTRA:PSG) commences a share repurchases on January 4, 2023, under the program mandated by the shareholders in the Annual General Meeting held on May 28, 2020. As per the mandate, the company is authorized to repurchase its own shares.
On January 3, 2023, the company announced a share repurchase program. Under the program, the company will repurchase up to 60,000 shares, for €1.5 million. The company intends to use the repurchased shares in accordance with the authorization of the General Meeting of May 28, 2020 for all legally permissible purposes. The program will start on January 4, 2023 and terminate at the end of July 3, 2023 at the latest. Reported Earnings • Jun 02
First quarter 2022 earnings: EPS in line with analyst expectations despite revenue beat First quarter 2022 results: EPS: €0.14 (up from €0.10 in 1Q 2021). Revenue: €20.6m (up 67% from 1Q 2021). Net income: €1.68m (up 43% from 1Q 2021). Profit margin: 8.2% (down from 9.5% in 1Q 2021). The decrease in margin was driven by higher expenses. Revenue exceeded analyst estimates by 6.3%. Earnings per share (EPS) were mostly in line with analyst estimates. Over the next year, revenue is forecast to grow 12%, compared to a 6.9% growth forecast for the industry in Germany. Major Estimate Revision • May 09
Consensus EPS estimates increase by 11% The consensus outlook for earnings per share (EPS) in 2022 has improved. 2022 revenue forecast increased from €77.2m to €80.4m. EPS estimate increased from €0.79 to €0.88 per share. Net income forecast to grow 0.09% next year vs 7.1% growth forecast for Pharmaceuticals industry in Germany. Consensus price target of €34.50 unchanged from last update. Share price rose 3.0% to €24.40 over the past week. Reported Earnings • May 01
Full year 2021 earnings: Revenues and EPS in line with analyst expectations Full year 2021 results: EPS: €0.89 (up from €0.89 in FY 2020). Revenue: €65.5m (up 3.6% from FY 2020). Net income: €10.7m (flat on FY 2020). Profit margin: 16% (in line with FY 2020). Revenue was in line with analyst estimates. Earnings per share (EPS) were also in line with analyst expectations. Over the next year, revenue is forecast to grow 18%, compared to a 8.1% growth forecast for the pharmaceuticals industry in Germany. Annonce • Apr 26
PharmaSGP Holding SE Provides Revenues Guidance for the Financial Year 2022 PharmaSGP Holding SE provided revenues guidance for the financial year 2022. After another record year, the company is targeting revenues of between EUR 78 million and EUR 82 million for the financial year 2022, up from EUR 65.3 million in the year before, equating to planned growth of at least 19.5%. Annonce • Apr 05
PharmaSGP Proposes Dividend for 2021 At the company's annual general meeting the management board of PharmaSGP Holding SE will propose a dividend amounting to 50% of net income for the year. Annonce • Feb 18
PharmaSGP Holding SE to Report Fiscal Year 2021 Results on Mar 15, 2022 PharmaSGP Holding SE announced that they will report fiscal year 2021 results on Mar 15, 2022 Reported Earnings • Dec 02
Third quarter 2021 earnings: Revenues exceed analysts expectations while EPS lags behind Third quarter 2021 results: EPS: €0.34 (up from €0.29 in 3Q 2020). Revenue: €19.9m (up 52% from 3Q 2020). Net income: €4.10m (up 20% from 3Q 2020). Profit margin: 21% (down from 26% in 3Q 2020). The decrease in margin was driven by higher expenses. Revenue exceeded analyst estimates by 25%. Earnings per share (EPS) missed analyst estimates by 6.3%. Earnings per share (EPS) missed analyst estimates by 6.3%. Over the next year, revenue is forecast to grow 16%, compared to a 6.9% growth forecast for the industry in Germany. Reported Earnings • Oct 01
Second quarter 2021 earnings released: EPS €0.25 (vs €0.32 in 2Q 2020) The company reported a poor second quarter result with weaker earnings and revenues, although profit margins were flat. Second quarter 2021 results: Revenue: €14.2m (down 24% from 2Q 2020). Net income: €3.02m (down 22% from 2Q 2020). Profit margin: 21% (in line with 2Q 2020). Valuation Update With 7 Day Price Move • Jul 21
Investor sentiment improved over the past week After last week's 16% share price gain to €23.30, the stock trades at a forward P/E ratio of 26x. Average forward P/E is 24x in the Pharmaceuticals industry in Europe. Total loss to shareholders of 22% over the past year. Major Estimate Revision • Jun 18
Consensus forecasts updated The consensus outlook for 2021 has been updated. 2021 revenue forecast increased from €58.2m to €61.0m. EPS estimate fell from €1.02 to €0.87 per share. Net income forecast to grow 27% next year vs 22% growth forecast for Pharmaceuticals industry in Germany. Consensus price target up from €32.50 to €35.00. Share price was steady at €21.50 over the past week. Reported Earnings • May 29
First quarter 2021 earnings released: EPS €0.10 (vs €0.27 in 1Q 2020) The company reported a poor first quarter result with weaker earnings, revenues and profit margins. First quarter 2021 results: Revenue: €12.4m (down 26% from 1Q 2020). Net income: €1.18m (down 64% from 1Q 2020). Profit margin: 9.5% (down from 19% in 1Q 2020). The decrease in margin was driven by lower revenue. Annonce • May 21
PharmaSGP Holding SE Provides Earnings Guidance for 2021 PharmaSGP Holding SE provided earnings guidance for 2021. For the period, The company anticipates revenues of between EUR 56 million and EUR 60 million. Valuation Update With 7 Day Price Move • May 13
Investor sentiment improved over the past week After last week's 15% share price gain to €18.35, the stock trades at a forward P/E ratio of 18x. Average forward P/E is 24x in the Pharmaceuticals industry in Europe. Reported Earnings • May 02
Full year 2020 earnings released: EPS €0.89 (vs €1.39 in FY 2019) The company reported a soft full year result with weaker earnings and profit margins, although revenues improved. Full year 2020 results: Revenue: €64.9m (up 3.7% from FY 2019). Net income: €10.6m (down 36% from FY 2019). Profit margin: 16% (down from 27% in FY 2019). The decrease in margin was driven by higher expenses. Major Estimate Revision • Feb 16
Analysts lower EPS estimates to €0.95 The 2020 consensus revenue estimate was lowered from €64.0m to €63.0m. Earning per share (EPS) estimate was also lowered from €1.13 to €0.95 for the same period. Net income is expected to shrink by 28% next year compared to 4.5% growth forecast for the Pharmaceuticals industry in Germany . The consensus price target was lowered from €37.50 to €32.50. Share price is down by 3.1% to €20.10 over the past week. Is New 90 Day High Low • Jan 15
New 90-day low: €19.76 The company is down 36% from its price of €31.00 on 16 October 2020. The German market is up 10.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 19% over the same period. Valuation Update With 7 Day Price Move • Jan 14
Investor sentiment deteriorated over the past week After last week's 17% share price decline to €21.05, the stock is trading at a trailing P/E ratio of 15.4x, down from the previous P/E ratio of 18.5x. This compares to an average P/E of 22x in the Pharmaceuticals industry in Europe. Valuation Update With 7 Day Price Move • Jan 11
Investor sentiment deteriorated over the past week After last week's 17% share price decline to €22.40, the stock is trading at a trailing P/E ratio of 16.4x, down from the previous P/E ratio of 19.8x. This compares to an average P/E of 22x in the Pharmaceuticals industry in Europe. Valuation Update With 7 Day Price Move • Dec 16
Investor sentiment improved over the past week After last week's 19% share price gain to €23.55, the stock is trading at a trailing P/E ratio of 17.3x, up from the previous P/E ratio of 14.5x. This compares to an average P/E of 23x in the Pharmaceuticals industry in Europe. Valuation Update With 7 Day Price Move • Dec 07
Market pulls back on stock over the past week After last week's 21% share price decline to €19.90, the stock is trading at a trailing P/E ratio of 14.6x, down from the previous P/E ratio of 18.5x. This compares to an average P/E of 23x in the Pharmaceuticals industry in Europe. Major Estimate Revision • Dec 02
Analysts lower EPS estimates to €1.13 The 2020 consensus revenue estimate was lowered from €67.0m to €64.0m. Earning per share (EPS) estimate was also lowered from €1.37 to €1.13 for the same period. Net income is expected to shrink by 5.6% next year compared to 13% growth forecast for the Pharmaceuticals industry in Germany . The consensus price target was lowered from €40.00 to €37.50. Share price is down by 11% to €23.45 over the past week. Is New 90 Day High Low • Nov 17
New 90-day low: €27.00 The company is down 14% from its price of €31.30 on 19 August 2020. The German market is up 2.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is down 1.0% over the same period. Is New 90 Day High Low • Oct 29
New 90-day low: €28.75 The company is down 7.0% from its price of €30.90 on 30 July 2020. The German market is down 5.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is down 4.0% over the same period. Reported Earnings • Oct 02
First half earnings released Over the last 12 months the company has reported total profits of €16.9m, up 7.7% from the prior year. Total revenue was €66.5m over the last 12 months, up 8.0% from the prior year. Annonce • Sep 10
PharmaSGP Holding SE to Report First Half, 2020 Final Results on Sep 30, 2020 PharmaSGP Holding SE announced that they will report first half, 2020 final results on Sep 30, 2020 Annonce • Sep 09
PharmaSGP Holding SE to Report First Half, 2020 Results on Sep 10, 2020 PharmaSGP Holding SE announced that they will report first half, 2020 results on Sep 10, 2020 Annonce • Jul 05
PharmaSGP Holding SE to Report Q3, 2020 Results on Nov 30, 2020 PharmaSGP Holding SE announced that they will report Q3, 2020 results on Nov 30, 2020 Annonce • Jun 19
PharmaSGP Holding SE has completed an IPO in the amount of €110.25 million. PharmaSGP Holding SE has completed an IPO in the amount of €110.25 million.
Security Name: Bearer Shares
Security Type: Common Stock
Securities Offered: 3,500,000
Price\Range: €31.5
Transaction Features: Regulation S; Rule 144A